Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 13/20 | 0.56 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.56 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.56 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 4/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1227036 | 0.99 | PTGDR2 (0.57) | PTGDR2TBXA2RPTGDRNR1H4RAB9A | |
| SCHEMBL1010989 | 0.92 | PTGDR2 (0.55) | PTGDR2TBXA2RPTGDRNR1H4RAB9A | |
| SCHEMBL1008723 | 0.89 | PTGDR2 (0.61) | PTGDR2TBXA2RPTGDRNR1H4MAPT | |
| SCHEMBL1010098 | 0.89 | PTGDR2 (0.54) | PTGDR2TBXA2RPTGDRNR1H4KMT2A | |
| SCHEMBL1011234 | 0.89 | PTGDR2 (0.59) | PTGDR2TBXA2RPTGDRRAB9AKMT2A | |
| SCHEMBL1009855 | 0.88 | PTGDR2 (0.58) | PTGDR2NR1H4RAB9ANPC1KMT2A | |
| SCHEMBL1011780 | 0.88 | PTGDR2 (0.52) | PTGDR2TBXA2RPTGDRNR1H4RAB9A | |
| SCHEMBL1650967 | 0.88 | PTGDR2 (0.71) | PTGDR2TBXA2RPTGDRNR1H4RAB9A | |
| SCHEMBL1008777 | 0.88 | PTGDR2 (0.57) | PTGDR2TBXA2RPTGDR | |
| SCHEMBL1226743 | 0.88 | NR1H4 (0.54) | PTGDR2NR1H4RAB9ANPC1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960393-B2 | Pyrimidine derivatives useful for the treatment of diseases mediated by CRTH2 | ACTIMIS PHARMACEUTICALS, INC. (US) | 2011-06-14 | — | — | US | claimed |
| JP-4671955-B2 | — | — | 2011-04-20 | — | — | JP | claimed |
| US-20100322980-A1 | PYRIMIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF DISEASES MEDIATED BY CRTH2 | GB005, INC. | 2010-12-23 | — | — | US | claimed |
| US-7812160-B2 | Pyrimidine derivatives useful for the treatment of diseases mediated by CRTH2 | ACTIMIS PHARMACEUTICALS, INC. (US) | 2010-10-12 | — | — | US | claimed |
| US-20070129355-A1 | G-protein-coupled chemoattractant receptor, expressed on T helper cells antagonists such as [4-(dimethylamino)-2-(4-{[4-(trifluoromethyl)benzoyl]amino}benzyl)-5-pyrimidinyl]acetic acid;, used for the treatment of allergic diseases, inflammatory diseases, eosinophil- and basophil-related diseases | ACTIMIS PHARMACEUTICALS, INC. (US) | 2007-06-07 | — | — | US | claimed |
| JP-2006524645-A | — | — | 2006-11-02 | — | — | JP | claimed |
| EP-1633726-A1 | PYRIMIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF DISEASES MEDIATED BY CRTH2 | Actimis Pharmaceuticals, Inc., (US) | 2006-03-15 | — | — | EP | claimed |
| EP-1471057-B1 | Pyrimidinylacetic acid derivatives useful for the treatment of diseases mediated by CRTH2 | ACTIMIS PHARMACEUTICALS INC (US) | 2006-01-18 | — | — | EP | claimed |
| WO-2004096777-A1 | PYRIMIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF DISEASES MEDIATED BY CRTH2 | ACTIMIS PHARMACEUTICALS, INC. (US) | 2004-11-11 | — | — | WO | claimed |
| EP-1471057-A1 | Pyrimidinylacetic acid derivatives useful for the treatment of diseases mediated by CRTH2 | Bayer HealthCare AG (DE) | 2004-10-27 | — | — | EP | claimed |
| US-20150051195-A1 | NOVEL VIRAL REPLICATION INHIBITORS | CISTIM LEUVEN VZW (BE) | 2015-02-19 | — | — | US | disclosed |
| US-8906906-B2 | Viral replication inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2014-12-09 | — | — | US | disclosed |
| EP-2462122-A1 | NOVEL VIRAL REPLICATION INHIBITORS | Katholieke Universiteit Leuven (BE) | 2012-06-13 | — | — | EP | disclosed |
| US-20120129840-A1 | NOVEL VIRAL REPLICATION INHIBITORS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2012-05-24 | — | — | US | disclosed |
| US-20120129820-A1 | NEW PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-24 | — | — | US | disclosed |
| US-20070129355-A1 | G-protein-coupled chemoattractant receptor, expressed on T helper cells antagonists such as [4-(dimethylamino)-2-(4-{[4-(trifluoromethyl)benzoyl]amino}benzyl)-5-pyrimidinyl]acetic acid;, used for the treatment of allergic diseases, inflammatory diseases, eosinophil- and basophil-related diseases | ACTIMIS PHARMACEUTICALS, INC. (US) | 2007-06-07 | — | — | US | disclosed |
| US-20070129355-A1 | G-protein-coupled chemoattractant receptor, expressed on T helper cells antagonists such as [4-(dimethylamino)-2-(4-{[4-(trifluoromethyl)benzoyl]amino}benzyl)-5-pyrimidinyl]acetic acid;, used for the treatment of allergic diseases, inflammatory diseases, eosinophil- and basophil-related diseases | ACTIMIS PHARMACEUTICALS, INC. (US) | 2007-06-07 | — | — | US | disclosed |
| US-20070129355-A1 | G-protein-coupled chemoattractant receptor, expressed on T helper cells antagonists such as [4-(dimethylamino)-2-(4-{[4-(trifluoromethyl)benzoyl]amino}benzyl)-5-pyrimidinyl]acetic acid;, used for the treatment of allergic diseases, inflammatory diseases, eosinophil- and basophil-related diseases | ACTIMIS PHARMACEUTICALS, INC. (US) | 2007-06-07 | — | — | US | disclosed |
| EP-1471057-B1 | Pyrimidinylacetic acid derivatives useful for the treatment of diseases mediated by CRTH2 | ACTIMIS PHARMACEUTICALS INC (US) | 2006-01-18 | — | — | EP | disclosed |
| EP-1471057-A1 | Pyrimidinylacetic acid derivatives useful for the treatment of diseases mediated by CRTH2 | Bayer HealthCare AG (DE) | 2004-10-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129840-A1 | NOVEL VIRAL REPLICATION INHIBITORS | MAVS, EIF2AK2, SAMHD1 | PTGDR2 4348/4885TBXA2R 4030/4885PTGDR 4221/4885 |
| US-20070129355-A1 | G-protein-coupled chemoattractant receptor, expressed on T helper cells antagonists such as [4-(dimethylamino)-2-(4-{[4-(trifluoromethyl)benzoyl]amino}benzyl)-5-pyrimidinyl]acetic acid;, used for the treatment of allergic diseases, inflammatory diseases, eosinophil- and basophil-related diseases | HRH2, HRH1, HRH4 | PTGDR2 78/4885TBXA2R 48/4885PTGDR 81/4885 |
| US-20100322980-A1 | PYRIMIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF DISEASES MEDIATED BY CRTH2 | HRH2, HRH1, CXCR2 | PTGDR2 73/4885TBXA2R 60/4885PTGDR 111/4885 |
| US-20150051195-A1 | NOVEL VIRAL REPLICATION INHIBITORS | MAVS, EIF2AK2, SAMHD1 | PTGDR2 4348/4885TBXA2R 4030/4885PTGDR 4221/4885 |
| US-20120129820-A1 | NEW PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISORDERS | HRH2, HRH1, HRH4 | PTGDR2 11/4885TBXA2R 20/4885PTGDR 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.